C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +4.76% and -5.35%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?